

CARB-X Antibacterial Treatment and Prevention Product Portfolio 2020.03.16

Sponsor	Product	Novelty			Description	Priority		Development Stage			
		New Abx Class	Non-traditional Product	New Target		CDC	WHO	Hit to Lead	Lead Optimization	Pre-Clinical	Phase I
Amicrobe	Amicidin-β		✓		Next-generation local antimicrobial	✓	✓			Broad spectrum	
Antabio	PEI		✓	✓	Pseudomonas elastase inhibitor	✓	✓		P. aeruginosa		
BB100, LLC (Bravos)	BB100		✓	✓	Monoclonal Antibody	✓	✓			Escherichia coli	
BioVersys	AVATAR-SA		✓	✓	Anti-virulence agent	✓	✓		S. aureus & MRSA		
Bugworks Research	GYROX	✓			Gyrase-topoisomerase inhibitor	✓	✓		Gram-negative activity		
Centauri Therapeutics	ABX01		✓		Dual-acting large molecule	✓	✓		Gram-negative activity		
ContraFect	Gram-negative aminidase	✓			Phage-encoded lytic peptide	✓	✓	Gram-negative activity			
ContraFect	Gram-negative lysins		✓	✓	Recombinant lysin protein	✓	✓	P. aeruginosa			
Debiopharm International SA	Debio1453	✓		✓	Narrow-spectrum inhibitors of FabI	✓	✓	Neisseria gonorrhoeae			
Debiopharm International SA	Debio1454	✓		✓	Narrow-spectrum inhibitors of FabI	✓	✓	Acinetobacter baumannii			
Entasis Therapeutics	ETX0282CPD P				Oral Gram-negative combination	✓	✓			Gram-negative activity	
Entasis Therapeutics	Non-BL PBPI	✓			Non-beta-lactam PBPI	✓	✓		Gram-negative activity		
Forge Therapeutics	FG-LpxC-LUNG	✓		✓	LpxC inhibitor	✓	✓	P. aeruginosa			
Forge Therapeutics	FG-LpxC-UTI	✓		✓	LpxC inhibitor	✓	✓	Gram-negative activity			
Idorsia	TopESKAPE	✓			Dual-acting topoisomerase inhibitor	✓	✓	Acinetobacter baumannii & Enterobacteriaceae			
Integrated BioTherapeutics	IBT-V02		✓		Multi-valent toxoid vaccine	✓	✓			S. aureus	
Lytica Therapeutics	StAMPs	✓	✓		Large molecule direct acting therapeutic	✓	✓	Gram-negative pathogens			
Microbiotix	Trans-Translation Inhibitors		✓	✓	Oral antibiotic	✓	✓	MDR N. gonorrhoea			
Microbiotix	T3SS inhibitor		✓	✓	Virulence modifier	✓	✓	P. aeruginosa			
MicRx	MRX-8				Soft drug polymyxin	✓	✓			Gram-negative activity	
Oxford Drug Design	DaaRSi	✓		✓	Dual-target Aminoacyl-tRNA Synthetase Inhibitor	✓	✓	Gram-negative activity			
Peptilogics	PLG0206	✓			Direct-acting engineered peptides	✓	✓			Broad Spectrum	
Polyphor	OMP/TA POL7306	✓		✓	Novel class, MDR/XDR ESKAPE	✓	✓			Gram-negative activity	
Seres Therapeutics	SER-155		✓		Microbiome-transplant patients	✓	✓	Broad spectrum activity vs CRE/VRE			
Summit Therapeutics	SMT-571 Series	✓		✓	Novel class, orally active antibiotic	✓	✓		Neisseria gonorrhoeae		
SutroVax, Inc.	GAS vaccine		✓	✓	Carbohydrate conjugate vaccine	✓	✓		Streptococcus pyogenes		
Taxis Pharmaceuticals	EPI-PA			✓	Efflux Pump Inhibitor	✓	✓	P. aeruginosa			
Techulon	PPNA-XPA	✓	✓	✓	Peptide-peptide nucleic acids (PPNAs)	✓	✓	A. baumannii & P. aeruginosa			
Trellis Bioscience	TRL1068		✓	✓	Monoclonal antibody	✓	✓			Broad spectrum	
Vaxxilon AG	VXN-319		✓	✓	Semi-synthetic conjugate vaccine	✓	✓		K. pneumoniae		
Vedanta	VE707		✓		Microbiome	✓	✓			CRE-ESBLs	
Venatorx	04CARB-X 0652	✓			Oral cyclic-boronate PGP inhibitor	✓	✓	Neisseria gonorrhoeae			
Zikani (formerly Macrolides)	Novel Macrolides				Novel macrolide antibiotics with Gram-negative activity	✓	✓		Gram-negative activity		

CARB-X Antibacterial Diagnostic Product Portfolio

Sponsor	Type	Technology	Description			
			Feasibility	Optimization	Development	Verification and Validation
Helixbind	Hospital-Based Dx	Automated culture-free pathogen ID			Bloodstream Infections	
Pattern Bioscience	Hospital-Based Dx	Digital Culture Single cell biometric analysis		RTIs, UTIs, BSIs		
Proteus	Hospital-Based Dx	Optical bacterial imaging		Respiratory Tract Infections		
Specific Diagnostics	Hospital-Based Dx	SMS Array for Phenotypic AST from Positive Blood Culture			Bloodstream Infections	
Talis	Near-Patient Dx	qLAMP for Pathogen ID; qLAMP for Phenotypic AST	AST for Neisseria gonorrhoeae; ID for Neisseria gonorrhoeae and Chlamydia trachomatis			

The above projects are Powered by CARB-X utilizing non-dilutive funding from BARDA, Wellcome Trust, Germany's Federal Ministry of Education and Research (BMBF), and NIAID, with some funding for specific projects from the UK Government's Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Bill & Melinda Gates Foundation. Characterizations of new Abx Class and New Target are by CARB-X, following Pew pipeline analysis: <http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development>. Other characterizations by CARB-X experts and external expert opinion. Abx = traditional small molecule antibiotic. Non-traditional Product = not a traditional small molecule antibiotic.